NewAmsterdam Pharma Company N.V. (NAMS) Earnings Call Transcripts
NewAmsterdam Pharma Company N.V.'s Latest Earnings Call - June 9, 2026
In the Q2 2026 earnings call for NewAmsterdam Pharma Company N.V. (NAMS:US), management highlighted significant progress in their PREVAIL trial, a pivotal study involving 9,500 patients. The interim analysis is set to commence by year-end, with results expected in Q1 2027, which could potentially accelerate the drug's market entry. Revenue and earnings figures were not disclosed in the call, and no guidance changes were mentioned, leaving investors with a focus on trial outcomes as the primary catalyst for stock movement.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | (null) |
| Earnings | (null) |
| Patient Enrollment in PREVAIL | 9,500 (positive) |
| Expected Event Rate Reduction | 21% (positive) |
| 4-Point MACE Event Increase | 20-24% (positive) |
| FDA Approval Timeline | Q1 2027 (positive) |
Guidance from management
Management did not provide specific revenue or earnings guidance but emphasized the importance of the upcoming interim analysis for the PREVAIL trial as a key milestone for the company.
What management said
Sure. Thanks. Thanks, everyone, for being here. We've had a really productive year firing on all cylinders. I mean our -- all our trials are rolling along on schedule or ahead of schedule. Of course, the most important being PREVAIL, which is our 9,500 patient outcome study and I think we announced just a few months ago that we're going to do an interim analysis based on a number of factors, we can go into more detai...
Well, you said event rate time point, which is going to be the end of this year approximately. And then it takes time to adjudicate all those events and go to growth before the DSMB, and then they have a charter, which they -- guides them on whether we hit the criteria for stopping the trial at that point?
What analysts pressed on
Analysts expressed concerns about the potential for placebo outperformance affecting trial results. There were also inquiries regarding the implications of changing the MACE endpoint definitions on regulatory approval and market perception.
Main topics on the call
- PREVAIL Trial Interim Analysis — Management confirmed that the interim analysis for the PREVAIL trial will begin by the end of 2026, with results anticipated in Q1 2027. CEO Michael Davidson stated, "this lower event rate is giving us, again, encouragem...
- Event Rate Observations — Management noted that the event rates in the PREVAIL trial are lower than expected, which is consistent with the BROADWAY trial results. Davidson emphasized, "we're seeing lower-than-expected event rates, which is consis...
- 4-Point MACE Definition Change — The company has updated the definition of the 4-point MACE endpoint to include total revascularization, which is expected to add 20-24% more events. Davidson explained, "the 4-point MACE was driven by 2 reasons... that m...
- Commercial Strategy Insights — Management indicated that the magnitude of MACE benefit (10% vs 20%) is less critical for market uptake than whether the study is positive. Davidson stated, "most doctors... just want to know the study is positive or not...
Read the full NewAmsterdam Pharma Company N.V. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 18 calls on record spanning March 4, 2024 to August 5, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 18 NewAmsterdam Pharma Company N.V. earnings call transcripts on record, spanning March 4, 2024 to August 5, 2026. Based on this history, NewAmsterdam Pharma Company N.V. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NAMS
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 18
- First call
- March 4, 2024
- Most recent
- August 5, 2026
- Reporting cadence
- quarterly